Literature DB >> 29948837

Development of an In Vitro Cardiac Ischemic Model Using Primary Human Cardiomyocytes.

Pezhman Hafez1, Shiplu R Chowdhury1, Shinsmon Jose2, Jia Xian Law1, B H I Ruszymah3, Abdul Rahman Mohd Ramzisham4, Min Hwei Ng5.   

Abstract

Developing experimental models to study ischemic heart disease is necessary for understanding of biological mechanisms to improve the therapeutic approaches for restoring cardiomyocytes function following injury. The aim of this study was to develop an in vitro hypoxic/re-oxygenation model of ischemia using primary human cardiomyocytes (HCM) and define subsequent cytotoxic effects. HCM were cultured in serum and glucose free medium in hypoxic condition with 1% O2 ranging from 30 min to 12 h. The optimal hypoxic exposure time was determined using Hypoxia Inducible Factor 1α (HIF-1α) as the hypoxic marker. Subsequently, the cells were moved to normoxic condition for 3, 6 and 9 h to replicate the re-oxygenation phase. Optimal period of hypoxic/re-oxygenation was determined based on 50% mitochondrial injury via 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide assay and cytotoxicity via lactate dehydrogenase (LDH) assay. It was found that the number of cells expressing HIF-1α increased with hypoxic time and 3 h was sufficient to stimulate the expression of this marker in all the cells. Upon re-oxygenation, mitochondrial activity reduced significantly whereas the cytotoxicity increased significantly with time. Six hours of re-oxygenation was optimal to induce reversible cell injury. The injury became irreversible after 9 h as indicated by > 60% LDH leakage compared to the control group cultured in normal condition. Under optimized hypoxic reoxygenation experimental conditions, mesenchymal stem cells formed nanotube with ischemic HCM and facilitated transfer of mitochondria suggesting the feasibility of using this as a model system to study molecular mechanisms of myocardial injury and rescue.

Entities:  

Keywords:  Cardiac ischemic model; Hypoxia/re-oxygenation; Mitochondrial transfer; Primary human cardiomyocytes; Reperfusion injury

Mesh:

Substances:

Year:  2018        PMID: 29948837     DOI: 10.1007/s13239-018-0368-8

Source DB:  PubMed          Journal:  Cardiovasc Eng Technol        ISSN: 1869-408X            Impact factor:   2.495


  10 in total

Review 1.  Current Progress in Tendon and Ligament Tissue Engineering.

Authors:  Wei Lee Lim; Ling Ling Liau; Min Hwei Ng; Shiplu Roy Chowdhury; Jia Xian Law
Journal:  Tissue Eng Regen Med       Date:  2019-06-26       Impact factor: 4.169

Review 2.  Treatment of spinal cord injury with mesenchymal stem cells.

Authors:  Ling Ling Liau; Qi Hao Looi; Wui Chuen Chia; Thayaalini Subramaniam; Min Hwei Ng; Jia Xian Law
Journal:  Cell Biosci       Date:  2020-09-22       Impact factor: 7.133

Review 3.  Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms.

Authors:  Brian D Guth; Michael Engwall; Sandy Eldridge; C Michael Foley; Liang Guo; Gary Gintant; John Koerner; Stanley T Parish; Jennifer B Pierson; Alexandre J S Ribeiro; Tanja Zabka; Khuram W Chaudhary; Yasunari Kanda; Brian Berridge
Journal:  Front Pharmacol       Date:  2019-08-09       Impact factor: 5.810

Review 4.  Mesenchymal Stromal Cell Mitochondrial Transfer as a Cell Rescue Strategy in Regenerative Medicine: A Review of Evidence in Preclinical Models.

Authors:  Yu Ling Tan; Sue Ping Eng; Pezhman Hafez; Norwahidah Abdul Karim; Jia Xian Law; Min Hwei Ng
Journal:  Stem Cells Transl Med       Date:  2022-08-23       Impact factor: 7.655

Review 5.  Effects of Lycopene Attenuating Injuries in Ischemia and Reperfusion.

Authors:  Sijia Wu; Xiajun Guo; Jia Shang; Yuanyuan Li; Wanglin Dong; Qianwen Peng; Zhenxing Xie; Chaoran Chen
Journal:  Oxid Med Cell Longev       Date:  2022-10-07       Impact factor: 7.310

Review 6.  Potential of Mesenchymal Stem Cells in the Rejuvenation of the Aging Immune System.

Authors:  Genieve Ee Chia Yeo; Min Hwei Ng; Fazlina Binti Nordin; Jia Xian Law
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

Review 7.  Large-Scale Expansion of Human Mesenchymal Stem Cells.

Authors:  Muhammad Najib Fathi Bin Hassan; Muhammad Dain Yazid; Mohd Heikal Mohd Yunus; Shiplu Roy Chowdhury; Yogeswaran Lokanathan; Ruszymah Bt Hj Idrus; Angela Min Hwei Ng; Jia Xian Law
Journal:  Stem Cells Int       Date:  2020-07-15       Impact factor: 5.443

8.  Lycopene protects against myocardial ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening.

Authors:  Xuying Li; Pengyu Jia; Zijun Huang; Shuang Liu; Jiaxin Miao; Yuxuan Guo; Nan Wu; Dalin Jia
Journal:  Drug Des Devel Ther       Date:  2019-07-11       Impact factor: 4.162

Review 9.  Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury.

Authors:  Gang-Un Kim; Soo-Eun Sung; Kyung-Ku Kang; Joo-Hee Choi; Sijoon Lee; Minkyoung Sung; Seung Yun Yang; Seul-Ki Kim; Young In Kim; Ju-Hyeon Lim; Min-Soo Seo; Gun Woo Lee
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

10.  Cardiac Ischemia On-a-Chip: Antiarrhythmic Effect of Levosimendan on Ischemic Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Mahmoud Gaballah; Kirsi Penttinen; Joose Kreutzer; Antti-Juhana Mäki; Pasi Kallio; Katriina Aalto-Setälä
Journal:  Cells       Date:  2022-03-19       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.